Highlights

  • Cryosite reported unaudited FY26 revenue of $16.7m, up 18%.
  • FY26 EBITDA reached $4.3m, up 27%, while NPAT rose 20% to $2.3m.
  • The completed Ferndell Street cool-room expansion adds capacity for temperature-controlled storage.
  • Development of the Adderley Street facility remained in progress at the FY26 trading update.
  • The business combines clinical trial logistics with biological, ultra-frozen and cryogenic storage services.

Cryosite Limited (ASX:CTE) provides specialist clinical trial logistics and temperature-controlled storage for pharmaceutical, biotechnology and medical research customers. Its services span receiving and storing trial materials, packaging, distribution, returns and biological sample management. Against this operational backdrop, Cryosite reported higher revenue and earnings for FY26 while progressing additional storage infrastructure intended to accommodate client activity.

FY26 Revenue and Earnings

In its July 2026 trading update, Cryosite (ASX:CTE) reported unaudited revenue of $16.7m for the financial year ended 30 June 2026, an increase of 18%. EBITDA rose 27% to $4.3m, while net profit after tax (NPAT) increased 20% to $2.3m. These were preliminary figures in the company’s trading update, rather than independently described here as final audited results.

The reported differences between revenue growth and EBITDA growth indicate that earnings increased faster than sales during the period. However, EBITDA does not represent cash generated by the business and excludes depreciation, interest and tax. For ASX:CTE, the distinction matters because investment in specialist temperature-controlled facilities involves equipment, monitoring systems and ongoing maintenance obligations.

Clinical Trial Logistics and Storage Services

Cryosite (ASX:CTE) handles investigational products and associated supplies used in clinical trials. According to the company’s website, its service offering includes importation, receipt, relabelling, secondary packaging, inventory control, distribution and reverse logistics. These functions help trial sponsors manage the movement and custody of materials that may require specific environmental conditions throughout storage and transport.

The South Granville facility supports controlled ambient storage at 15°C to 25°C, refrigerated storage at 2°C to 8°C, frozen storage and liquid-nitrogen cryogenic storage. The company also identifies monitored security and temperature alarms, backup generators and validated warehouse management systems among its facility features. Such infrastructure is relevant to medicines and biological materials whose handling requirements differ considerably from conventional warehouse goods.

Additional Capacity for FY27 Operations

Cryosite (ASX:CTE) said its Ferndell Street cool-room expansion had been completed by the July 2026 trading update. At the same time, the Adderley Street build-out was progressing. The company identified FY27 as a period focused on converting added capacity into client activity, without specifying a guaranteed utilisation level or revenue contribution in that update.

Greater physical capacity is not equivalent to immediate earnings growth. New space must be equipped, qualified where required and matched with customer demand. Cryosite (ASX:CTE) therefore faces a practical connection between infrastructure spending, utilisation and the timing of service revenues. Changes in customer trial schedules may affect how quickly newly available space is occupied.

Operating Considerations and Financial Discipline

Clinical logistics businesses are exposed to operational risks including equipment malfunction, temperature excursions, delays in shipments and changing regulatory requirements. Sponsors may also reschedule or discontinue trials, altering storage and handling volumes. Cryosite’s disclosed backup power, monitoring and inventory systems address aspects of operational control, but their presence cannot eliminate every disruption or compliance risk.

For ASX:CTE, revenue and EBITDA growth should be considered alongside capital expenditure, actual operating cash flow and funding requirements for new facilities. The relative pace of facility development and new customer activity can influence working capital and future reported margins.

Key Insights

Cryosite’s unaudited FY26 update shows increases in revenue, EBITDA and NPAT alongside investment in additional specialist storage capacity. Its business depends on managing regulated, temperature-sensitive products throughout clinical trial supply chains. The interaction between facility utilisation, service volumes, equipment requirements and operating controls is central to understanding the company’s reported activities, without treating capacity expansion as a guaranteed financial outcome.